ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Ascendis Pharma A/S
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 20-F on Feb 11, 2026
$229.95+4.70 (+2.09%)
Close on Oct 19, 2026
Share price
+$19.45 (+9.24%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Ascendis Pharma A/S grew revenue 98.0% to €720.13M over the twelve months to Dec 31, 2025.
Revenue
€720.13M
+98.0% vs. a year earlier
Operating income
-€136.27M
TTM Q4 2025
EPS, diluted
-3.76 EUR
TTM Q4 2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- €720.13M
- Net income
- -€228.03M
- EPS, diluted
- -3.76 EUR
- Diluted shares
- 61M
Valuation needs the share price. It fills in once daily prices are connected and converted from EUR.
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
€720.13M+98.0% YoY
Gross profit
€625.22M+95.8% YoY
Operating income
-€136.27M
Net income
-€228.03M
EPS, diluted
-3.76 EUR
Free cash flow
–
Reported period